NO912750L - Fremgangsmaate for fremstilling av terapeutisk aktive tiokso-heterocykliske forbindelser. - Google Patents
Fremgangsmaate for fremstilling av terapeutisk aktive tiokso-heterocykliske forbindelser.Info
- Publication number
- NO912750L NO912750L NO91912750A NO912750A NO912750L NO 912750 L NO912750 L NO 912750L NO 91912750 A NO91912750 A NO 91912750A NO 912750 A NO912750 A NO 912750A NO 912750 L NO912750 L NO 912750L
- Authority
- NO
- Norway
- Prior art keywords
- tioxo
- procedure
- preparation
- heterocyclic compounds
- therapeutic active
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- -1 oxy, thio, sulphinyl Chemical group 0.000 abstract 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 abstract 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 125000005551 pyridylene group Chemical group 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP90402034 | 1990-07-13 | ||
| EP91400079 | 1991-01-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO912750D0 NO912750D0 (no) | 1991-07-12 |
| NO912750L true NO912750L (no) | 1992-01-14 |
Family
ID=26127361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO91912750A NO912750L (no) | 1990-07-13 | 1991-07-12 | Fremgangsmaate for fremstilling av terapeutisk aktive tiokso-heterocykliske forbindelser. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5240941A (cs) |
| EP (1) | EP0466452B1 (cs) |
| JP (1) | JPH04243877A (cs) |
| KR (1) | KR920002561A (cs) |
| AT (1) | ATE128133T1 (cs) |
| AU (1) | AU638579B2 (cs) |
| CA (1) | CA2046006A1 (cs) |
| CS (1) | CS214891A3 (cs) |
| DE (1) | DE69113148T2 (cs) |
| DK (1) | DK0466452T3 (cs) |
| ES (1) | ES2076472T3 (cs) |
| FI (1) | FI913369A7 (cs) |
| GB (1) | GB9113137D0 (cs) |
| GR (1) | GR3017453T3 (cs) |
| HU (1) | HUT61999A (cs) |
| IE (1) | IE912138A1 (cs) |
| IL (1) | IL98603A0 (cs) |
| MX (1) | MX174406B (cs) |
| NO (1) | NO912750L (cs) |
| NZ (1) | NZ238703A (cs) |
| PT (1) | PT98292A (cs) |
| TW (1) | TW235918B (cs) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9018134D0 (en) * | 1989-09-29 | 1990-10-03 | Ici Plc | Heterocyclic derivatives |
| IE911853A1 (en) * | 1990-06-21 | 1992-01-01 | Ici Plc | Heterocyclene derivatives |
| IE914005A1 (en) * | 1990-12-14 | 1992-06-17 | Zeneca Ltd | Novel intermediates |
| GB9122590D0 (en) * | 1991-10-24 | 1991-12-04 | Lilly Industries Ltd | Pharmaceutical compounds |
| AU4444393A (en) * | 1992-09-01 | 1994-03-10 | Zeneca Limited | Pyrrolidine derivatives |
| US5354865A (en) * | 1992-09-10 | 1994-10-11 | Abbott Laboratories | Phenylmethyl derivatives having lipoxygenase inhibitory activity |
| IL109254A (en) * | 1993-04-29 | 1999-03-12 | Zeneca Ltd | Tetrahydropyran and tetrahydrofuran ether derivatives their preparation and pharmaceutical compositions comprising them |
| EP0702678A1 (en) * | 1993-06-07 | 1996-03-27 | Zeneca Limited | Aniline derivatives |
| JPH08511254A (ja) * | 1993-06-07 | 1996-11-26 | ゼネカ・リミテッド | ２−オキソ−１，２，３，４−テトラヒドロキノリン誘導体 |
| US5459271A (en) * | 1993-07-20 | 1995-10-17 | Merck Frosst Canada, Inc. | Arylbicyclooctanes as inhibitors of leukotriene biosynthesis |
| US5643933A (en) * | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| US6677364B2 (en) * | 1998-04-20 | 2004-01-13 | G.D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| SV2005001973A (es) | 2003-12-12 | 2005-11-04 | Wyeth Corp | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) |
| US8158362B2 (en) | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
| US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| ES2423010T3 (es) | 2006-04-04 | 2013-09-17 | The Regents Of The University Of California | Derivados de pirazolopirimidina para su uso como antagonistas de cinasa |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| KR101660050B1 (ko) | 2008-01-04 | 2016-09-26 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン， エルエルシー | キナーゼ阻害剤および使用方法 |
| NZ590258A (en) | 2008-07-08 | 2013-10-25 | Intellikine Llc | Kinase inhibitors and methods of use |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| EP2358720B1 (en) | 2008-10-16 | 2016-03-02 | The Regents of The University of California | Fused ring heteroaryl kinase inhibitors |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
| AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| CN103491962B (zh) | 2011-02-23 | 2016-10-12 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| ES2984771T3 (es) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| RU2015115631A (ru) | 2012-09-26 | 2016-11-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Модулирование ire1 |
| PL2914296T5 (pl) | 2012-11-01 | 2022-01-17 | Infinity Pharmaceuticals, Inc. | Leczenie nowotworu z zastosowaniem modulatorów izoform kinazy PI3 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| ES2657451T3 (es) | 2013-04-19 | 2018-03-05 | Incyte Holdings Corporation | Heterocíclicos bicíclicos como inhibidores del FGFR |
| PH12016500582B1 (en) | 2013-10-04 | 2023-06-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN113616656B (zh) | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CN107438607B (zh) | 2015-02-20 | 2021-02-05 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP3268085A4 (en) | 2015-03-13 | 2018-10-31 | The Board of Trustees of The Leland Stanford Junior University | Ltb4 inhibition to prevent and treat human lymphedema |
| JP6980649B2 (ja) | 2015-09-14 | 2021-12-15 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| IL263680B1 (en) | 2016-06-24 | 2025-06-01 | Infinity Pharmaceuticals Inc | Pi3k inhibitors for use in combination with a second therapeutic agent in treating, managing, or preventing cancer |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| JP7568512B2 (ja) | 2018-05-04 | 2024-10-16 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の塩 |
| FI3788047T3 (fi) | 2018-05-04 | 2024-11-02 | Incyte Corp | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| TW202334089A (zh) | 2021-11-02 | 2023-09-01 | 美商夫雷爾醫療公司 | Ｐｐａｒｇ反向激動劑及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3661917A (en) * | 1970-05-21 | 1972-05-09 | Smith Kline French Lab | 3-sulfonamido-4-hydroxyphenyl-2-piperidylcarbinols |
| US3743737A (en) * | 1970-05-21 | 1973-07-03 | Smith Kline French Lab | 3-sulfonamido-4-hydroxyphenyl-2-piperindinylcarbinol compositions |
| IE56702B1 (en) * | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
| NZ213986A (en) * | 1984-10-30 | 1989-07-27 | Usv Pharma Corp | Heterocyclic or aromatic compounds, and pharmaceutical compositions containing such |
| US4839369A (en) * | 1985-04-16 | 1989-06-13 | Rorer Pharmaceutical Corporation | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
| US4876346A (en) * | 1985-05-02 | 1989-10-24 | American Home Products Corporation | Quinoline compounds |
| EP0271287A3 (en) * | 1986-12-11 | 1990-06-13 | Merck Frosst Canada Inc. | Quinoline dioic acids and amides |
| US4920133A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920130A (en) * | 1987-11-02 | 1990-04-24 | Rorer Pharamceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920132A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920131A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4918081A (en) * | 1988-06-20 | 1990-04-17 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene d4 |
| EP0349062A1 (en) * | 1988-06-27 | 1990-01-03 | Merck Frosst Canada Inc. | Quinoline ether alkanoic acid |
| GB8926981D0 (en) * | 1988-12-23 | 1990-01-17 | Ici Plc | Heterocyclic derivatives |
| IE70521B1 (en) * | 1989-02-28 | 1996-12-11 | Zeneca Pharma Sa | Heterocycles with inhibitory activity of 5-lipoxygenase |
| GB9018134D0 (en) * | 1989-09-29 | 1990-10-03 | Ici Plc | Heterocyclic derivatives |
-
1991
- 1991-06-18 GB GB919113137A patent/GB9113137D0/en active Pending
- 1991-06-20 IE IE213891A patent/IE912138A1/en unknown
- 1991-06-24 IL IL98603A patent/IL98603A0/xx unknown
- 1991-06-26 NZ NZ238703A patent/NZ238703A/xx unknown
- 1991-06-26 AU AU79337/91A patent/AU638579B2/en not_active Ceased
- 1991-06-28 CA CA002046006A patent/CA2046006A1/en not_active Abandoned
- 1991-07-08 HU HU912295A patent/HUT61999A/hu unknown
- 1991-07-09 ES ES91306213T patent/ES2076472T3/es not_active Expired - Lifetime
- 1991-07-09 DK DK91306213.9T patent/DK0466452T3/da active
- 1991-07-09 AT AT91306213T patent/ATE128133T1/de not_active IP Right Cessation
- 1991-07-09 DE DE69113148T patent/DE69113148T2/de not_active Expired - Fee Related
- 1991-07-09 EP EP91306213A patent/EP0466452B1/en not_active Expired - Lifetime
- 1991-07-11 PT PT98292A patent/PT98292A/pt not_active Application Discontinuation
- 1991-07-11 US US07/728,371 patent/US5240941A/en not_active Expired - Fee Related
- 1991-07-11 CS CS912148A patent/CS214891A3/cs unknown
- 1991-07-11 FI FI913369A patent/FI913369A7/fi not_active Application Discontinuation
- 1991-07-12 MX MX9100201A patent/MX174406B/es not_active IP Right Cessation
- 1991-07-12 JP JP3172295A patent/JPH04243877A/ja active Pending
- 1991-07-12 NO NO91912750A patent/NO912750L/no unknown
- 1991-07-12 KR KR1019910012111A patent/KR920002561A/ko not_active Withdrawn
- 1991-07-24 TW TW080105761A patent/TW235918B/zh active
-
1995
- 1995-09-21 GR GR940403950T patent/GR3017453T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB9113137D0 (en) | 1991-08-07 |
| CA2046006A1 (en) | 1992-01-14 |
| HUT61999A (en) | 1993-03-29 |
| DE69113148D1 (de) | 1995-10-26 |
| ATE128133T1 (de) | 1995-10-15 |
| DE69113148T2 (de) | 1996-03-28 |
| ES2076472T3 (es) | 1995-11-01 |
| FI913369A7 (fi) | 1992-01-14 |
| CS214891A3 (en) | 1992-02-19 |
| JPH04243877A (ja) | 1992-08-31 |
| TW235918B (cs) | 1994-12-11 |
| US5240941A (en) | 1993-08-31 |
| EP0466452A2 (en) | 1992-01-15 |
| IL98603A0 (en) | 1992-07-15 |
| AU7933791A (en) | 1992-01-16 |
| EP0466452A3 (en) | 1992-08-19 |
| IE912138A1 (en) | 1992-01-15 |
| NO912750D0 (no) | 1991-07-12 |
| HU912295D0 (en) | 1991-12-30 |
| MX174406B (es) | 1994-05-13 |
| KR920002561A (ko) | 1992-02-28 |
| PT98292A (pt) | 1992-05-29 |
| NZ238703A (en) | 1994-01-26 |
| DK0466452T3 (da) | 1996-01-02 |
| AU638579B2 (en) | 1993-07-01 |
| EP0466452B1 (en) | 1995-09-20 |
| GR3017453T3 (en) | 1995-12-31 |
| FI913369A0 (fi) | 1991-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO912750L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive tiokso-heterocykliske forbindelser. | |
| MY106366A (en) | Bicyclic heterocyclic pryan derivatives and their use as inhibitors of 5-lipoxygenase | |
| NO904249L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterosykliske derivater. | |
| NO900916L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser. | |
| GR3019161T3 (en) | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | |
| BR9103433A (pt) | Derivados de 4-benzil-isoxazol | |
| NO900918D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske cykliske etere. | |
| NO900917L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske cykloalkaner. | |
| DK147588A (da) | Benzoxazinderivat samt fremgangsmaade til fremstilling deraf | |
| EP1219607A4 (en) | INTEGRASE INHIBITORS WITH AN AROMATIC HETEROCYCLUS | |
| EP0462831A3 (en) | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | |
| ATE147376T1 (de) | Heterocyclische derivate | |
| DK0501354T3 (da) | Antikataraktmiddel |